Advexin Improves Survival in Head and Neck Cancer
Source: CancerConsultants.com Author: staff The targeted agent Advexin (p53 tumor suppressor therapy) improves survival compared with methotrexate among head and neck cancer patients with the p53 biomarkers. These results were recently presented at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. Head and neck cancers originate in the oral cavity (lip, mouth, tongue), salivary glands, paranasal sinuses, nasal cavity, pharynx (upper back part of the throat), larynx (voice box), and lymph nodes in the upper part of the neck. Worldwide, head and neck cancer is diagnosed in approximately 640,000 people annually and is responsible for approximately 350,000 deaths each year. Patients whose head and neck cancer has returned following prior therapy have suboptimal long-term outcomes with standard therapies and research continues to evaluate novel therapeutic approaches to improve these outcomes. The field of genetics is emerging as a potential therapeutic tool in the treatment of cancer. Although still in clinical trials, researchers are testing and exploring the use of genetic strategies for several types of cancer. Gene therapy, a type of treatment in the field of genetics, often involves the insertion of a functional, normal gene into a cell that has a dysfunctional gene that may cause or contribute to the growth of cancer. One gene, called the p53 gene, is of major focus in the evaluation of gene therapy since a significant portion of cancers have been shown to have a mutation (alteration) of this gene. The [...]